Philip Burrows

Abstract:

The Compact Linear Collider is one of the two main European options for a collider in a post Large Hadron Collider era. This is a linear e+e-collider with three center-of-mass energy stages: 380 GeV, 1.5 TeV, and 3 TeV. The luminosity performance of the first stage at 380 GeV is presented including the impact of static and dynamic imperfections. These calculations are performed with fully realistic tracking simulations from the exit of the damping rings to the interaction point and including beam-beam effects in the collisions. A luminosity of 4.3×1034 cm-2 s-1 can be achieved with a perfect collider, which is almost three times the nominal luminosity target of 1.5×1034 cm-2 s-1. In simulations with static imperfections, a luminosity of 2.35×1034 cm-2 s-1 or greater is achieved by 90% of randomly misaligned colliders. Expressed as a percentage of the nominal luminosity target, this is a surplus of approximately 57%. Including the impact of ground motion, a luminosity surplus of 53% or greater can be expected for 90% of colliders. The average expected luminosity is 2.8×1034 cm-2 s-1, which is almost twice the nominal luminosity target.

Abstract:

The “Laser-hybrid Accelerator for Radiobiological Applications,” LhARA, is conceived as a novel, flexible facility dedicated to the study of radiobiology. The technologies demonstrated in LhARA, which have wide application, will be developed to allow particle-beam therapy to be delivered in a new regimen, combining a variety of ion species in a single treatment fraction and exploiting ultra-high dose rates. LhARA will be a hybrid accelerator system in which laser interactions drive the creation of a large flux of protons or light ions that are captured using a plasma (Gabor) lens and formed into a beam. The laser-driven source allows protons and ions to be captured at energies significantly above those that pertain in conventional facilities, thus evading the current space-charge limit on the instantaneous dose rate that can be delivered. The laser-hybrid approach, therefore, will allow the radiobiology that determines the response of tissue to ionizing radiation to be studied with protons and light ions using a wide variety of time structures, spectral distributions, and spatial configurations at instantaneous dose rates up to and significantly beyond the ultra-high dose-rate “FLASH” regime. It is proposed that LhARA be developed in two stages. In the first stage, a programme of in vitro radiobiology will be served with proton beams with energies between 10 and 15 MeV. In stage two, the beam will be accelerated using a fixed-field alternating-gradient accelerator (FFA). This will allow experiments to be carried out in vitro and in vivo with proton beam energies of up to 127 MeV. In addition, ion beams with energies up to 33.4 MeV per nucleon will be available for in vitro and in vivo experiments. This paper presents the conceptual design for LhARA and the R&D programme by which the LhARA consortium seeks to establish the facility.